These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
460 related articles for article (PubMed ID: 19607756)
1. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756 [TBL] [Abstract][Full Text] [Related]
2. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia. Seillier A; Martinez AA; Giuffrida A Neuropsychopharmacology; 2013 Aug; 38(9):1816-24. PubMed ID: 23563893 [TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Guidali C; Viganò D; Petrosino S; Zamberletti E; Realini N; Binelli G; Rubino T; Di Marzo V; Parolaro D Int J Neuropsychopharmacol; 2011 Feb; 14(1):17-28. PubMed ID: 20196921 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of fatty acid amide hydrolase modulates anxiety-like behavior in PCP-treated rats. Seillier A; Giuffrida A Pharmacol Biochem Behav; 2011 Jun; 98(4):583-6. PubMed ID: 21421000 [TBL] [Abstract][Full Text] [Related]
5. The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: Further evidence for transporter-mediated endocannabinoid release. Seillier A; Giuffrida A Neuropharmacology; 2018 Mar; 130():1-9. PubMed ID: 29169961 [TBL] [Abstract][Full Text] [Related]
6. Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system. Seillier A; Giuffrida A Eur Neuropsychopharmacol; 2016 Feb; 26(2):298-309. PubMed ID: 26706691 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of fatty acid amide hydrolase reverses aberrant prefrontal gamma oscillations in the sub-chronic PCP model for schizophrenia. Seillier A Exp Brain Res; 2024 May; 242(5):1149-1160. PubMed ID: 38489023 [TBL] [Abstract][Full Text] [Related]
8. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Moise AM; Eisenstein SA; Astarita G; Piomelli D; Hohmann AG Psychopharmacology (Berl); 2008 Oct; 200(3):333-46. PubMed ID: 18545985 [TBL] [Abstract][Full Text] [Related]
9. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Hansson AC; Bermúdez-Silva FJ; Malinen H; Hyytiä P; Sanchez-Vera I; Rimondini R; Rodriguez de Fonseca F; Kunos G; Sommer WH; Heilig M Neuropsychopharmacology; 2007 Jan; 32(1):117-26. PubMed ID: 16482090 [TBL] [Abstract][Full Text] [Related]
10. Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats. Viana TG; Hott SC; Resstel LB; Aguiar DC; Moreira FA Psychopharmacology (Berl); 2015 May; 232(9):1545-53. PubMed ID: 25388290 [TBL] [Abstract][Full Text] [Related]
11. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Nucci C; Gasperi V; Tartaglione R; Cerulli A; Terrinoni A; Bari M; De Simone C; Agrò AF; Morrone LA; Corasaniti MT; Bagetta G; Maccarrone M Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):2997-3004. PubMed ID: 17591864 [TBL] [Abstract][Full Text] [Related]
12. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2. Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084 [TBL] [Abstract][Full Text] [Related]
13. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Falenski KW; Thorpe AJ; Schlosburg JE; Cravatt BF; Abdullah RA; Smith TH; Selley DE; Lichtman AH; Sim-Selley LJ Neuropsychopharmacology; 2010 Jul; 35(8):1775-87. PubMed ID: 20357755 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Spradley JM; Guindon J; Hohmann AG Pharmacol Res; 2010 Sep; 62(3):249-58. PubMed ID: 20416378 [TBL] [Abstract][Full Text] [Related]
16. Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation. Eisenstein SA; Holmes PV; Hohmann AG Synapse; 2009 Nov; 63(11):941-50. PubMed ID: 19593824 [TBL] [Abstract][Full Text] [Related]
17. Role of the endocannabinoid system in the dorsal hippocampus in the cardiovascular changes and delayed anxiety-like effect induced by acute restraint stress in rats. Hartmann A; Fassini A; Scopinho A; Correa FM; Guimarães FS; Lisboa SF; Resstel LB J Psychopharmacol; 2019 May; 33(5):606-614. PubMed ID: 30789299 [TBL] [Abstract][Full Text] [Related]
18. Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB Stern CAJ; da Silva TR; Raymundi AM; de Souza CP; Hiroaki-Sato VA; Kato L; Guimarães FS; Andreatini R; Takahashi RN; Bertoglio LJ Neuropharmacology; 2017 Oct; 125():220-230. PubMed ID: 28754373 [TBL] [Abstract][Full Text] [Related]
19. Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597. Matricon J; Seillier A; Giuffrida A Neurosci Res; 2016 Sep; 110():49-58. PubMed ID: 27091613 [TBL] [Abstract][Full Text] [Related]
20. Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD. Fidelman S; Mizrachi Zer-Aviv T; Lange R; Hillard CJ; Akirav I Eur Neuropsychopharmacol; 2018 May; 28(5):630-642. PubMed ID: 29519609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]